NeuroReport

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Pharmaceutical industry, Residential care, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Health insurance, Residential care, Pharmaceutical industry, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

Retrieved on: 
Tuesday, August 17, 2021
Company, Terminology, Glioblastoma, SCLC, Securities Exchange Act of 1934, PP2A, Drug Quality and Security Act, Cancer, U.S. Securities and Exchange Commission, Addiction, GLOBE, NeuroReport, Research, Triple-negative breast cancer, Death, Central nervous system, CA, Marketing, Cell, MDS, GBM, Securities Act of 1933, Methamphetamine, Patient, Squamous cell carcinoma, Toxicity, Dwarfism, Pharmaceutical industry

PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, noted that in pre-clinical studies its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to reduce behavioral sensitization underlying addiction to methamphetamine (METH). Behavioral sensitization is widely considered a key neurobiological mechanism in drug addiction.

Key Points: 
  • Behavioral sensitization is widely considered a key neurobiological mechanism in drug addiction.
  • Studies in animal models have shown that dysregulation in the activity of PP2A could be a factor in diseases of the central nervous system, including drug addiction.
  • A recent scientific paper ( Shang et al., NeuroReport, April 2021 ) explains how LB-100, by inhibiting PP2A, blocked METH-induced behavioral sensitization in rodents.
  • Last month, Lixte commented on outside research citing LB-100s PP2A inhibition as a potential therapeutic strategy for triple-negative breast cancer .